High Level of Irisin as a Marker of Malnutrition in Head and Neck Cancer Patients Subjected to Radiotherapy

Iwona Homa-Mlak; Radosław Mlak; Anna Brzozowska; Marcin Mazurek; Tomasz Powrózek; Monika Prendecka-Wróbel; Aneta Szudy-Szczyrek; Piotr Dreher; Katarzyna Kamińska; Teresa Małecka-Massalska; Alicja Wójcik-Załuska

doi:10.12659/MSM.936857

01 September 2022 : Clinical Research

High Level of Irisin as a Marker of Malnutrition in Head and Neck Cancer Patients Subjected to Radiotherapy

Iwona Homa-Mlak^1ACDEF*, Radosław Mlak^1ACDEF, Anna Brzozowska^2BDF, Marcin Mazurek^1CEF, Tomasz Powrózek^1CDE, Monika Prendecka-Wróbel^1CEF, Aneta Szudy-Szczyrek^2ADE, Piotr Dreher^3CEF, Katarzyna Kamińska^4F, Teresa Małecka-Massalska^1ACEF, Alicja Wójcik-Załuska^5CEG

DOI: 10.12659/MSM.936857

Med Sci Monit 2022; 28:e936857

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Influence of demographic and clinical factors on irisin level in HNC patients.

Factor		Irisin level median (95% CI)	p
Gender	Male	1.36 (1.22–1.46)	0.1006
Gender	Female	1.12 (0.74–1.50)	0.1006
Age (years)	≥65	1.41 (1.21–1.65)	0.1378
Age (years)	<65	1.27 (1.10–1.41)	0.1378
Histopathological diagnosis	Carcinoma planoepitheliale	1.34 (1.17–1.44)	0.4969
Histopathological diagnosis	Other	1.22 (−)	0.4969
Tumor location	Upper and middle	1.53 (1.05–1.71)	0.7166
	Lower	1.33 (1.17–1.41)	0.7166
	Lower and middle	1.33 (1.17–1.42)	0.4869
	Upper	1.55 (−)	0.4869
T stage	T1–T2	1.27 (0.79–1.57)	0.2970
T stage	T3–T4	1.34 (1.18–1.45)	0.2970
N stage	N0	1.38 (1.22–1.56)	0.5191
N stage	N1–N3	1.24 (1.14–1.44)	0.5191
M stage	M0	1.35 (1.20–1.45)	0.2282
M stage	Mx and M1	1.17 (−)	0.2282
Performance status (ECOG)	1	1.33 (1.19–1.43)	0.5198
Performance status (ECOG)	2	1.47 (−)	0.5198
Alcohol consumption	Yes	1.43 (1.14–1.59)	0.2120
Alcohol consumption	No	1.23 (1.15–1.39)	0.2120
Tobacco smoking	Yes	1.38 (1.17–1.51)	0.3543
Tobacco smoking	No	1.24 (0.99–1.43)	0.3543
Treatment	Surgery+RTH	1.39 (1.19–1.46)	0.5936
	Other	1.23 (1.13–1.55)	0.5936
	Surgery+chemoradiation	1.22 (1.07–1.53)	0.5701
	Other	1.37 (1.18–1.49)	0.5701
	RTH alone	1.13 (−)	0.1796
	Other	1.34 (1.22–1.45)	0.1796
	Induction CTH+RTH	1.55 (−)	0.7906
	Other	1.33 (1.18–1.42)	0.7906
	Concurrent chemoradiation	1.53 (−)	0.2933
	Other	1.28 (1.17–1.43)	0.2933
CTH – chemotherapy; ECOG – Eastern Cooperative Oncology Group; M – metastatic spread; N – lymph node involvement; RTH – radiotherapy; T – tumor site and size; TNM –Tumor, Node, Metastasis staging.

Back to the Article

High Level of Irisin as a Marker of Malnutrition in Head and Neck Cancer Patients Subjected to Radiotherapy

Your Privacy